Flavonol-based inhibitors targeting acetohydroxyacid synthase in mycobacterium tuberculosis
Computationally designed flavonol and 5-hydroxyflavonol compounds intended to inhibit acetohydroxyacid synthase (AHAS) in M. tuberculosis, leveraging cross-species herbicide activity as a starting point for novel antitubercular drug discovery.
Overview
This research proposes a series of flavonol and 5-hydroxyflavonol derivatives designed to inhibit acetohydroxyacid synthase (AHAS), a key enzyme in the branched-chain amino acid biosynthesis pathway of Mycobacterium tuberculosis. The project is grounded in the observation that the herbicide sulfometuron methyl suppresses M. tuberculosis growth through AHAS inhibition, suggesting that AHAS is a viable target for antitubercular drug development. Because AHAS inhibition translates across species, the proposed compounds may also exhibit herbicidal activity, offering dual-application potential.
Technical specifications
- Target enzyme: Acetohydroxyacid synthase (AHAS), specifically the IlvB1 catalytic subunit of M. tuberculosis
- Modeling approach: Homology modeling using PDB templates 1YBH and 1T9C to construct a structural model of M. tuberculosis IlvB1
- Design strategy: Multiple drug design approaches applied to elucidate structure–activity relationships and optimize flavonol scaffolds for AHAS binding
- Compound classes: Flavonols and 5-hydroxyflavonols, selected for their ability to interact with the AHAS active site
- Cross-species rationale: Sulfometuron methyl herbicide activity against M. tuberculosis provides proof-of-concept that AHAS inhibitors can be effective antimicrobial agents
Technology readiness level
The project is at an early computational design stage. A homology model of the M. tuberculosis AHAS catalytic subunit has been generated, and candidate flavonol inhibitors have been designed. Experimental validation procedures and future validation plans are not detailed in the available proposal information, so the readiness level for biological or field application remains to be established.
About Heinrich Heine Universität Düsseldorf
Heinrich Heine Universität Düsseldorf is a comprehensive public research university anchored by a major medical faculty and a modern science campus. An integrated university hospital and shared core facilities enable clinical translation and access to specialized instrumentation for joint studies. Companies collaborate through on‑campus spaces, contract research, and tailored partnership models, with quick reach to suppliers and manufacturing across North Rhine‑Westphalia’s Rhine‑Ruhr corridor. Research is supported by competitive funding from the German Research Foundation and federal and state ministries, alongside European Union programs. A dedicated technology transfer office manages IP, licensing, and startup support to accelerate industry uptake.
delivered to your inbox.